Clinical Analysis of Pediatric Acute Myeloid Leukemia with CCLG-AML 2015 Regimen.
10.19746/j.cnki.issn.1009-2137.2022.02.009
- Author:
Ping WANG
1
;
Hao XIONG
2
;
Jian-Xin LI
3
;
Zhuo WANG
3
;
Li YANG
3
;
Fang TAO
3
;
Zhi CHEN
3
;
Yu DU
3
;
Ai-Ping ZHANG
1
;
Lin-Lin LUO
1
Author Information
1. School of Medicine of Jianghan University， Wuhan 430056， Hubei Province， China,Wuhan Children's Hospital (Wuhan Matemal and Child Healthcare Hospital), Tongji Medical College， Huazhong University of Science & Techology， Wuhan 430016， Hubei Province， China.
2. Wuhan Children's Hospital (Wuhan Matemal and Child Healthcare Hospital), Tongji Medical College， Huazhong University of Science & Techology， Wuhan 430016， Hubei Province， China,E-mail：22587481@qq.com.
3. Wuhan Children's Hospital (Wuhan Matemal and Child Healthcare Hospital), Tongji Medical College， Huazhong University of Science & Techology， Wuhan 430016， Hubei Province， China.
- Publication Type:Journal Article
- Keywords:
CCLG-AML-2015;
acute myeloid leukemia;
hematopoietic stem cell transplantation;
pediatric;
prognosis;
protocol
- MeSH:
Child;
Disease-Free Survival;
Humans;
Leukemia, Myeloid, Acute/drug therapy*;
Prognosis;
Remission Induction;
Retrospective Studies
- From:
Journal of Experimental Hematology
2022;30(2):373-380
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To analyze the clinical effects of CCLG-AML-2015 protocol on newly diagnosed children with acute myeloid leukemia (AML).
METHODS:The clinical data of 60 newly diagnosed AML children in the Department of Hematology and Oncology, Wuhan Children's Hospital from August 2015 to September 2019 were summarized, the effect of chemotherapy using the CCLG-AML-2015 regimen (hereinafter referred to as the 2015 regimen) were retrospectively analyzed. 42 children with AML treated by the AML-2006 regimen (hereinafter referred to as the 2006 regimen) from February 2010 to July 2015 were used as control group.
RESULTS:There were no statistical differences between the 2015 regimen group and the 2006 regimen group in sex, age at first diagnosis, and risk stratification (P>0.05). The complete remission rate of bone marrow cytology after induction of 1 course of chemotherapy (84.7% vs 73.1%, P=0.155), and minimal residual disease detection (MRD) negative (42.3% vs 41.4%, P=0.928) in the 2015 regimen group were not statistically different than those in the 2006 regimen group. The bone marrow cytology CR (98.1% vs 80.6%, P=0.004) and MRD negative (83.3% vs 52.8%, P=0.002) in the 2015 regimen group after 2 courses of induction were higher than those in the 2006 regimen group. The 5-year overall survival (OS) rate in the 2015 regimen group (62.3%±6.4% vs 20.6%±6.4%, P=0.001), the 5-year disease-free survival (EFS) rate (61.0%±6.4% vs 21.0% ±6.4% , P=0.001) were better than those in the 2006 regimen group. The 5-year OS and EFS of high-risk transplant patients in the 2015 regimen group were significantly better than those of high-risk non-transplant patients (OS: 86.6%±9.0% vs 26.7%±11.4%, P=0.000; EFS: 86.6%±9% vs 26.7%±11.4%, P=0.000).
CONCLUSION:The 2015 regimen can increase the CR rate after 2 courses of induction compared with the 2006 regimen. High-risk children receiving hematopoietic stem cell transplantation can significantly improve the prognosis.
